Teradyne (TER) executive sells 788 shares under 10b5-1 plan

Rhea-AI Filing Summary

Teradyne, Inc. reported an insider stock sale by executive Mills Regan. Regan, who serves as President, Product Test, sold 788 shares of Teradyne common stock in an open-market transaction at a price of $332.87 per share on February 25, 2026. After this transaction, Regan directly owned 11,889.3452 shares of Teradyne common stock. The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025, which is designed to allow insiders to sell shares according to a preset schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mills Regan

(Last) (First) (Middle)

C/O TERADYNE, INC.

600 RIVERPARK DRIVE

(Street)

NORTH READING MA 01864

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TERADYNE, INC [ TER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Product Test

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		788	D	$332.87	11,889.3452	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold pursuant to a sales plan adopted by the Reporting Person on November 25, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

	/s/ Ryan E. Driscoll, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teradyne (TER) executive Mills Regan report?

Mills Regan reported selling 788 shares of Teradyne common stock in an open-market transaction at $332.87 per share. The sale was disclosed on a Form 4 and reflects activity by Teradyne’s President, Product Test.

When did Mills Regan’s Teradyne (TER) stock sale take place?

The reported Teradyne stock sale by Mills Regan occurred on February 25, 2026. On that date, Regan completed an open-market transaction involving 788 common shares at a price of $332.87 per share.

How many Teradyne (TER) shares does Mills Regan own after the reported sale?

After the reported sale, Mills Regan directly owns 11,889.3452 shares of Teradyne common stock. This figure reflects the remaining direct holdings following the disposition of 788 shares in the open-market transaction.

Was Mills Regan’s Teradyne (TER) stock sale part of a 10b5-1 plan?

Yes. The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. Such plans allow insiders to schedule share sales in advance, helping separate trading decisions from later market-sensitive information.

What role does Mills Regan hold at Teradyne (TER)?

Mills Regan serves as Teradyne’s President, Product Test. This officer position makes Regan a reporting person for SEC purposes, requiring disclosure of transactions in Teradyne common stock on forms such as Form 4.

What type of transaction code was used for Mills Regan’s Teradyne (TER) sale?

The transaction was coded “S” on Form 4, indicating a sale in an open market or private transaction. This code confirms the reported activity was a disposition of Teradyne common stock rather than an acquisition or option exercise.